Low-Voltage Zone Ablation for Persistent AF: Trial Data
Pulmonary vein isolation remains the cornerstone of atrial fibrillation management. However, clinicians often observe suboptimal long-term outcomes in patients with persistent atrial fibrillation. To address this challenge, researchers evaluated individualized low-voltage zone ablation as an adjunctive strategy. Consequently, electroanatomical mapping helps identify fibrotic substrate that sustains complex arrhythmias.
Evidence on Low-Voltage Zone Ablation in Persistent AF
The IDEAL-AF randomized clinical trial enrolled adult patients undergoing first-time catheter ablation for persistent atrial fibrillation. Specifically, investigators identified 209 patients who exhibited significant left atrial low-voltage zones of 3.0 cm² or larger. The trial randomized these participants to receive either pulmonary vein isolation alone or adjunctive substrate ablation. After twelve months of follow-up, the combination strategy achieved superior rhythm control without antiarrhythmic drugs. Arrhythmia-free survival reached 67.6% in the adjunctive ablation cohort compared to 37.4% in the isolation-only cohort. Furthermore, the adjunctive approach demonstrated an unadjusted absolute risk difference of 30.3% in maintaining sinus rhythm.
Procedural Safety and Clinical Implications
Notably, patients receiving low-voltage zone ablation reported meaningful improvements in health-related quality of life. Additionally, the time to first arrhythmia recurrence significantly favored the individualized substrate modification arm. Importantly, procedural safety profiles remained comparable between both study cohorts without an increase in severe adverse events. Therefore, mapping atrial substrate provides actionable targets for electrophysiologists treating diseased atrial tissue. In conclusion, tailored substrate ablation provides substantial clinical benefit for selected patients presenting with substantial low-voltage zones.
Frequently Asked Questions
Q1: What is the primary benefit of low-voltage zone ablation?
Adjunctive low-voltage zone ablation significantly improves arrhythmia-free survival at 12 months in patients with persistent atrial fibrillation and diseased substrate.
Q2: Does adjunctive low-voltage ablation increase procedural risks?
In the IDEAL-AF trial, serious adverse event rates remained similar between pulmonary vein isolation alone and adjunctive low-voltage ablation.
Q3: How were low-voltage zones defined in the IDEAL-AF trial?
Investigators defined significant low-voltage zones as electroanatomically mapped diseased atrial tissue measuring 3.0 cm² or greater outside isolated veins.
References
- Paul Nordin A et al. Low-Voltage Ablation in Persistent Atrial Fibrillation: The IDEAL-AF Randomized Clinical Trial. JAMA. 2026 Aug 30. doi: 10.1001/jama.2026.17274. PMID: 42669133.
- Pranata R et al. Low-Voltage Area Ablation for Persistent Atrial Fibrillation: Meta-Analysis and Trial Sequential Analysis of RCTs. Pacing Clin Electrophysiol. 2026 Aug 16. doi: 10.1111/pace.70392. PMID: 42604946.
